Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead. Learn why ASMB stock is a buy.
Zacks Investment Research on MSN
Gilead Sciences (GILD) sees a more significant dip than broader market: Some facts to know
In the latest close session, Gilead Sciences (GILD) was down 1.48% at $134.28. This change lagged the S&P 500's daily loss of 1.01%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, ...
The stock's fall snapped a two-day winning streak.
Check out the latest Gilead Sciences Inc. (GILD) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.
Gilead Sciences’ Up To Date campaign with comedians Nicole Byer and Devon Walker hopes to normalize conversations about HIV prevention, testing and PrEP. The campaign targets Black women through ...
As people with HIV live longer, diabetes is becoming an increasingly important contributor to morbidity and mortality, ...
Gamblers can now bet on how experimental drugs will perform in clinical trials—and if they’ll get FDA approval.
Bill Lawrence, W. Kamau Bell, Karamo Brown and Baron Davis also join the lineup for the July 22 event, where Gilead Sciences ...
Making a creative pharma campaign that earns recognition at the prestigious Cannes Lions Festival of Creativity is a beast. Gilead Sciences conquered the task with the help of some AI-generated ...
Background and aims Restoration of intestinal barrier integrity and function in inflammatory bowel disease (IBD) has been ...
RICHMOND, Va. — The Virginia Department of Health (VDH) has finalized a plan to pay millions of dollars back to a pharmaceutical company to resolve a billing issue that forced cuts to programs that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results